Skip to main content
RocheIn development

Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio

Source: Autobound Signal API · 87 signals tracked for Roche · updated

Get Roche's live signals in Claude or ChatGPT, or by API

AskWhat changed at Roche this week? Use Autobound signals for roche.com.

What happened

Roche showcased Phase III clinical results for its cancer drug Divarasib in advanced lung cancer.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Basel, 19 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data, including two late-breaking abstracts, across lung, breast and other cancers at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting, held from 23 to 27 October in Madrid. "Our presentations at ESMO 2026 highlight the depth and impact of Roche's oncology pipeline, driven by emerging science capable of bringing new treatment benefits across diverse and high-unmet-need cancers," said Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development. "From establishing head-to-head superiority with divarasib in KRAS G12C-mutated lung cancer to advancing patient-centered oral SERD therapies like giredestrant and next-generation ADCs such as Tam-Peli, we are committed to delivering medicines that not only extend life, but also seek to improve treatment experience, tolerability and quality of life for people living with cancer. Divarasib demonstrated superior efficacy and best-in-class potential in KRAS G12C NSCLC Roche will share phase III Krascendo 1 results, which demonstrated divarasib's best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer. Giredestrant data support its potential to become the new standard of care in early-stage and advanced breast cancer Roche will present new data highlighting the...

Keep reading with a free account

The rest of this article, and every signal for Roche, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
Divarasib

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical

Extraction

Confidence
90%
Detected
Oct 19, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Roche and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Roche this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/bbb4adda-0707-fe42-ee19-6e0cc98e127d returns this record as JSON. POST /v1/companies/enrich returns every signal for roche.com.

{
  "signal_id": "bbb4adda-0707-fe42-ee19-6e0cc98e127d",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-19T07:37:37+00:00",
  "company": {
    "name": "Roche",
    "domain": "roche.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/10/19/3382972/0/en/roche-to-present-pivotal-data-at-esmo-2026-showcasing-advances-across-its-lung-and-breast-cancer-late-stage-portfolio.html",
    "title": "Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio",
    "excerpt": "Basel, 19 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data, including two late-breaking abstracts, across lung, breast and other cancers at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting, held from 23 to 27 October in Madrid. “Our presentations at ESMO 2026 highlight the depth and impact of Roche’s oncology pipeline, driven by emerging science capable of bringing new treatment benefits across diverse and high-unmet-need cancers,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “From establishing head-to-head superiority with divarasib in KRAS G12C-mutated lung cancer to advancing patient-centered oral SERD therapies like giredestrant and next-generation ADCs such as Tam-Peli, we are committed to delivering medicines that not only extend life, but also seek to improve treatment experience, tolerability and quality of life for people living with cancer. Divarasib demonstrated superior efficacy and best-in-class potential in KRAS G12C NSCLC Roche will share phase III Krascendo 1 results, which demonstrated divarasib’s best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer. Giredestrant data support its potential to become the new standard of care in early-stage and advanced breast cancer Roche will present new data highlighting the...",
    "product": "Divarasib",
    "summary": "Roche showcased Phase III clinical results for its cancer drug Divarasib in advanced lung cancer.",
    "planning": false,
    "image_url": "https://ml-eu.globenewswire.com/Resource/Download/696b7c85-2d23-4f5e-a77b-8c6b2fa45d47",
    "confidence": 0.9,
    "product_data": {
      "name": "Divarasib",
      "full_text": "Divarasib",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-19T05:00:00Z",
    "article_sentence": "Roche will share phase III Krascendo 1 results, which demonstrated divarasib’s best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.